home / stock / nrbo / nrbo quote
Last: | $4.4702 |
---|---|
Change Percent: | 1.71% |
Open: | $4.6 |
Close: | $4.4702 |
High: | $4.8 |
Low: | $4.4702 |
Volume: | 33,590 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.4702 | $4.6 | $4.4702 | $4.8 | $4.4702 | 33,590 | 07-03-2024 |
$4.68 | $4.73 | $4.68 | $4.793 | $4.25 | 61,741 | 07-02-2024 |
$4.54 | $4.99 | $4.54 | $5.03 | $4.53 | 182,473 | 07-01-2024 |
$4.84 | $4.86 | $4.84 | $4.885 | $4.4 | 65,825 | 06-28-2024 |
$4.8 | $4.83 | $4.8 | $5.3 | $4.65 | 150,900 | 06-27-2024 |
$4.83 | $4.85 | $4.83 | $5.3 | $4.26 | 462,827 | 06-26-2024 |
$4.26 | $4.11 | $4.26 | $4.26 | $3.86 | 442,403 | 06-25-2024 |
$4.08 | $3.32 | $4.08 | $4.2 | $3.32 | 313,546 | 06-24-2024 |
$4.06 | $4.04 | $4.06 | $4.154 | $3.9 | 43,078 | 06-21-2024 |
$4.1 | $3.7 | $4.1 | $4.25 | $3.7 | 82,923 | 06-20-2024 |
$3.84 | $3.93 | $3.84 | $3.93 | $3.63 | 20,632 | 06-19-2024 |
$3.84 | $3.93 | $3.84 | $3.93 | $3.63 | 20,632 | 06-18-2024 |
$3.8272 | $3.87 | $3.8272 | $3.926 | $3.7 | 12,306 | 06-17-2024 |
$3.81 | $3.94 | $3.81 | $3.95 | $3.8 | 11,487 | 06-14-2024 |
$3.92 | $3.9749 | $3.92 | $3.9749 | $3.88 | 6,218 | 06-13-2024 |
$3.8409 | $3.9942 | $3.8409 | $4.05 | $3.8377 | 6,483 | 06-12-2024 |
$4.02 | $3.902 | $4.02 | $4.0899 | $3.9 | 3,187 | 06-11-2024 |
$3.9 | $3.8 | $3.9 | $4 | $3.8 | 8,628 | 06-10-2024 |
$3.93 | $4 | $3.93 | $4.0901 | $3.91 | 7,369 | 06-07-2024 |
$4.03 | $4.03 | $4.03 | $4.05 | $3.9287 | 12,286 | 06-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
NeuroBo Pharmaceuticals Inc. Company Name:
NRBO Stock Symbol:
NASDAQ Market:
NeuroBo Pharmaceuticals Inc. Website:
NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire Top-Line Data Readout From the Single Ascending Dose Part 1 Expected in the Third Quarter of 2024, and From the Multiple Asce...
NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire $20 million upfront with up to an additional $50 million of aggregate gross proceeds upon ...
NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire $20 million upfront with up to an additional $50 million of aggregate gross proceeds upon the exercise in...